VERONA PHARMA
Updated 264 days ago
Public Limited Company
- Active - 05375156 (CH)
- Age: 19 years
- ID: 32126001/89
ONE CENTRAL SQUARE CARDIFF UNITED KINGDOM CF10 1FS
• 72110 - Research and experimental development on biotechnology
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company") announces the submission of a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease ("COPD")... We are focused on developing our product candidate, ensifentrine, which we believe has the potential to become an important and novel treatment for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other respiratory diseases, including asthma. We own the global development and commercialization rights to ensifentrine except in Greater China where we have formed a partnership with Nuance Pharma... Initially, we are developing ensifentrine for the US market and seeking strategic partnerships in other regions. We have formed a $219 million strategic collaboration with Nuance Pharma to develop and commercialize..
Also known as: VERONA PHARMA PLC
Previous names: ISIS RESOURCES PLC
Registration numbers: 05375156 (CH)